These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 39044494)

  • 1. Safety Profile of a Cognitively Unimpaired Older Population with Elevated Cerebral Amyloid in a 4.5-Year Clinical Trial.
    Yaari R; Holdridge KC; Mancini M; Rafii MS; Case M; Battioui C; Sims JR; Aisen PS; Sperling RA
    J Prev Alzheimers Dis; 2024; 11(4):857-868. PubMed ID: 39044494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amyloid and Tau Prediction of Cognitive and Functional Decline in Unimpaired Older Individuals: Longitudinal Data from the A4 and LEARN Studies.
    Sperling RA; Donohue MC; Rissman RA; Johnson KA; Rentz DM; Grill JD; Heidebrink JL; Jenkins C; Jimenez-Maggiora G; Langford O; Liu A; Raman R; Yaari R; Holdridge KC; Sims JR; Aisen PS
    J Prev Alzheimers Dis; 2024; 11(4):802-813. PubMed ID: 39044488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
    Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
    Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging.
    Lowe SL; Duggan Evans C; Shcherbinin S; Cheng YJ; Willis BA; Gueorguieva I; Lo AC; Fleisher AS; Dage JL; Ardayfio P; Aguiar G; Ishibai M; Takaichi G; Chua L; Mullins G; Sims JR
    J Prev Alzheimers Dis; 2021; 8(4):414-424. PubMed ID: 34585215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Change in Digital Cognitive Test Performance between Solanezumab and Placebo Groups in Preclinical Alzheimer's Disease: Secondary Analyses from the A4 Study.
    Papp KV; Maruff P; Rentz DM; Donohue MC; Liu A; Aisen PS; Sperling RA
    J Prev Alzheimers Dis; 2024; 11(4):846-856. PubMed ID: 39044493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
    Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R
    Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterizing Clinical Progression in Cognitively Unimpaired Older Individuals with Brain Amyloid: Results from the A4 Study.
    Rentz DM; Rosenberg PB; Sperling RA; Donohue MC; Raman R; Liu A; Aisen PS
    J Prev Alzheimers Dis; 2024; 11(4):814-822. PubMed ID: 39044489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trial of Solanezumab in Preclinical Alzheimer's Disease.
    Sperling RA; Donohue MC; Raman R; Rafii MS; Johnson K; Masters CL; van Dyck CH; Iwatsubo T; Marshall GA; Yaari R; Mancini M; Holdridge KC; Case M; Sims JR; Aisen PS;
    N Engl J Med; 2023 Sep; 389(12):1096-1107. PubMed ID: 37458272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid-Related Imaging Abnormalities and Other MRI Findings in a Cognitively Unimpaired Population With and Without Cerebral Amyloid.
    Yaari R; Holdridge KC; Choi J; Donohue MC; Kantarci K; Jack CR; Zuk SM; Sims JR; Johnson KA; Aisen PS; Sperling RA
    J Prev Alzheimers Dis; 2022; 9(4):617-624. PubMed ID: 36281665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
    Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
    Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between Plasma P-Tau217 and Amyloid PET in Racial and Ethnic Underrepresented Groups (RE-URG) Compared with Non RE-URG in LEARN and A4.
    Molina-Henry D; Langford O; Donohue MC; Raman R; Aisen P; Johnson KA; Rissman RA; Sperling R
    J Prev Alzheimers Dis; 2024; 11(4):831-837. PubMed ID: 39044491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal Trajectories of the Cognitive Function Index in the A4 Study.
    Amariglio RE; Grill JD; Rentz DM; Marshall GA; Donohue MC; Liu A; Aisen PS; Sperling RA
    J Prev Alzheimers Dis; 2024; 11(4):838-845. PubMed ID: 39044492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of Cortical and Subcortical Amyloid Burden across Stages of Preclinical Alzheimer's Disease.
    Edmonds EC; Bangen KJ; Delano-Wood L; Nation DA; Furst AJ; Salmon DP; Bondi MW;
    J Int Neuropsychol Soc; 2016 Nov; 22(10):978-990. PubMed ID: 27903335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal Phospho-tau217 Predicts Amyloid Positron Emission Tomography in Asymptomatic Alzheimer's Disease.
    Rissman RA; Donohue MC; Langford O; Raman R; Abdel-Latif S; Yaari R; Holdridge KC; Sims JR; Molina-Henry D; Jimenez-Maggiora G; Johnson KA; Aisen PS; Sperling RA
    J Prev Alzheimers Dis; 2024; 11(4):823-830. PubMed ID: 39044490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The A4 study: β-amyloid and cognition in 4432 cognitively unimpaired adults.
    Insel PS; Donohue MC; Sperling R; Hansson O; Mattsson-Carlgren N
    Ann Clin Transl Neurol; 2020 May; 7(5):776-785. PubMed ID: 32315118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease.
    Egan MF; Kost J; Voss T; Mukai Y; Aisen PS; Cummings JL; Tariot PN; Vellas B; van Dyck CH; Boada M; Zhang Y; Li W; Furtek C; Mahoney E; Harper Mozley L; Mo Y; Sur C; Michelson D
    N Engl J Med; 2019 Apr; 380(15):1408-1420. PubMed ID: 30970186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons.
    Donohue MC; Sperling RA; Petersen R; Sun CK; Weiner MW; Aisen PS;
    JAMA; 2017 Jun; 317(22):2305-2316. PubMed ID: 28609533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tilavonemab in early Alzheimer's disease: results from a phase 2, randomized, double-blind study.
    Florian H; Wang D; Arnold SE; Boada M; Guo Q; Jin Z; Zheng H; Fisseha N; Kalluri HV; Rendenbach-Mueller B; Budur K; Gold M
    Brain; 2023 Jun; 146(6):2275-2284. PubMed ID: 36730056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.